Therapy Areas: Autoimmune
Anokion Initiates Patient Dosing in Phase 1 Trial of ANK-700 for the Treatment of Multiple Sclerosis
23 March 2021 - - Swiss biotechnology company Anokion SA has initiated patient dosing in its Phase 1 clinical trial to evaluate ANK-700 for the treatment of people with relapsing remitting multiple sclerosis, the company said.

The MoveS-it Study (Multiple Sclerosis Study of ANK-700 to Assess Safety and Immune Tolerance) is a randomized, double-blind, placebo-controlled, first-in-human study designed to evaluate the safety and tolerability of single and multiple ascending doses of ANK-700.

MS is a demyelinating disease of the central nervous system, in which the immune system attacks the myelin sheath in the brain and spinal cord.

ANK-700 aims to re-educate the immune system by inducing antigen-specific tolerance to myelin-based autoantigens in order to reduce neuroinflammation in the brain and spinal cord.

The MoveS-it Study will enroll up to 40 patients at up to 10 sites across the United States.

The primary endpoint of the trial is safety and tolerability, the secondary endpoint is pharmacokinetics of ANK-700, and other exploratory endpoints include assessments of immunological biomarker responses.

Anokion SA is a Swiss biotechnology company targeting autoimmune diseases.

The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes.
Login
Username:

Password: